Terns Pharmaceuticals Inc

Discover how Terns Pharmaceuticals is pioneering oral, targeted liver‑disease and cancer drugs, driving global biotech innovation and improving patient outcomes.

Discover why Terns Pharmaceuticals’ latest CARDINAL trial data, analyst upgrades, and strong pipeline are driving a surge in investor confidence and share price.

Terns Pharmaceuticals Inc. is navigating market fluctuations with a strategic focus on liver disease and cancer treatments, positioning itself for long-term growth despite current financial challenges.

Terns Pharmaceuticals Inc. is navigating market volatility with a strategic focus on developing innovative treatments for liver disease and cancer, positioning the company for continued growth and success.

Terns Pharmaceuticals Inc is a biopharmaceutical company specializing in molecularly-targeted and oral molecule drugs, aiming to tackle challenging diseases like liver disease and cancer with innovative treatments.

Terns Pharmaceuticals Inc’s stock has experienced significant volatility, with a 52-week high of $11.4 USD and a low of $1.865 USD, as the company navigates financial challenges and market expectations in the biopharmaceutical sector.